Please use this identifier to cite or link to this item: https://has.hcu.ac.th/jspui/handle/123456789/3664
Title: Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents
Authors: Suvadee Supreeyasakon
Jantima Traipattanakul
Jatapat Hemapanpairoa
Piraporn Juntanawiwat
Wichai Santimaleeworagun
สุวดี สุปรียสกนธ์
จาฏพัจน์ เหมพรรณไพเราะ
วิชัย สันติมาลีวรกุล
Huachiew Chalermprakiet University. Faculty of Pharmacy
Phramongkutklao Hospital and College of Medicine. Department of Internal Medicine
Silpakorn University. Faculty of Pharmacy
Phramongkutklao Hospital. Division of Microbiology
Silpakorn University. Faculty of Pharmacy
Keywords: Pseudomonas aeruginosa
ซูโดโมนาสแอรูจิโนซา
Carbapenem
คาร์บาร์พีเนม
Sepsis
การติดเชื้อในกระแสเลือด
Antimicrobial resistance
การดื้อยาต้านจุลชีพ
Issue Date: 2024
Citation: PLoS ONE November 19, 2024 : e0313944
Abstract: Pseudomonas aeruginosa associated with hospital-acquired infection is often resistant to various antibiotics and is associated with high mortality worldwide. The appropriate treatment of Pseudomonas aeruginosa resistant to carbapenems but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents (Car-R/NonCar-S P. aeruginosa) remains unclear. This retrospective study evaluated risk factors for 14-day and 30-day mortality among treatment regimens against Car-R/NonCar-S P. aeruginosa. This study enrolled 180 patients with Car-R/NonCar-S P. aeruginosa infection at Phramongkutklao Hospital between January 2019 and December 2023. The 14-day and 30-day mortality rates were 18.3% and 28.9%, respectively. Bloodstream infection (OR 1.97, 95% CI 0.88–4.43), septic shock (OR 3.3, 95% CI 1.30–8.40), Acute Physiology and Chronic Health Evaluation (APACHE) II < 14 (OR 0.13, 95% CI 0.03–0.54), Sequential Organ Failure Assessment (SOFA) <7 (OR 0.25, 95% CI 0.11–0.56), and Pitt bacteremia score <4 (OR 0.16, 95% CI 0.05–0.47) were associated with 14-day mortality. There was a higher 14-day and 30-day mortality in patients treated with piperacillin/tazobactam or aminoglycosides but there was no significant difference among antipseudomonal antimicrobial agents in the treatment of Car-R/NonCar-S P. aeruginosa infection. We supported the use of traditional antipseudomonal β-lactam agents to treat Car-R/NonCar-S P. aeruginosa infections, however the use of piperacillin/tazobactam might be concerned in some cases and further investigations were needed.
Description: สามารถเข้าถึงบทความฉบับเต็ม (Full Text) ได้ที่: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0313944
URI: https://has.hcu.ac.th/jspui/handle/123456789/3664
Appears in Collections:Pharmaceutical Sciences - Artical Journals



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.